Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ACLX

Arcellx Inc

Feb 23 • 04:00PM ET

113.75

+49.64 77.43 %

Healthcare • Biotechnology • USA • NASD

Feb 23, 9:45 AMGilead to acquire Arcellx for $115 per share in cash plus $5 CVR in ~$7.8B anito‑cel multiple myeloma deal

Peers: ALLO GILD CRSP NTLA FATE EDIT BLUE SGMO PSTX VCNX

| Held by: VTI XBI IWM VB VXF VBK TCAF IBB IWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	22.67%	Shs Outstand	57.78M	Perf Week	66.06%
Market Cap	6.58B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-0.71%	Shs Float	44.71M	Perf Month	65.77%
Enterprise Value	6.17B	PEG	-	EPS next Q	-1.04	Inst Own	93.99%	Short Float	20.37%	Perf Quarter	26.92%
Income	-217.90M	P/S	183.21	EPS this Y	-102.56%	Inst Trans	1.40%	Short Ratio	5.68	Perf Half Y	58.49%
Sales	35.90M	P/B	14.91	EPS next Y	10.16%	ROA	-30.67%	Short Interest	9.11M	Perf YTD	74.46%
Book/sh	7.63	P/C	14.26	EPS next 5Y	3.50%	ROE	-47.18%	52W High	94.07 20.92%	Perf Year	78.43%
Cash/sh	7.98	P/FCF	-	EPS past 3/5Y	-3.30% -31.14%	ROIC	-44.92%	52W Low	47.86 137.67%	Perf 3Y	315.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	80.99%	Volatility	3.57% 3.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	171.80	EPS Y/Y TTM	-425.41%	Oper. Margin	-675.67%	ATR (14)	6.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.99	Sales Y/Y TTM	-76.96%	Profit Margin	-607.01%	RSI (14)	83.72	Recom	2.67
Dividend Gr. 3/5Y	- -	Current Ratio	3.99	EPS Q/Q	-105.12%	SMA20	61.15%	Beta	0.19	Target Price	112.08
Payout	-	Debt/Eq	0.12	Sales Q/Q	-80.99%	SMA50	66.74%	Rel Volume	30.63	Prev Close	64.11
Employees	163	LT Debt/Eq	0.10	Earnings	Nov 05 AMC	SMA200	57.47%	Avg Volume	1.61M	Price	113.75
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.75% -51.96%	Trades		Volume	32,901,972	Change	77.43%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$82
Jan-07-26	Resumed	UBS	Buy	$100
Dec-22-25	Initiated	Wells Fargo	Overweight	$100
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Oct-16-25	Initiated	Stifel	Buy	$129
Jun-17-25	Initiated	Citigroup	Buy	$110
Oct-08-24	Initiated	Redburn Atlantic	Buy	$109
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36

Show Previous Ratings

Feb-23-26 05:33PM	Stocks to Watch Monday Recap: Diamondback, Netflix, Novo Nordisk, Lilly (The Wall Street Journal) +77.43%
05:22PM	Are ACLX, VRE, UHG, EHAB Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:27PM	These Stocks Are Todays Movers: Novo Nordisk, Lilly, PayPal, Arcellx, CrowdStrike, KKR, Strategy, and More (Barrons.com)
04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
03:44PM	This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. (Barrons.com)
01:50PM	Loading…
01:50PM	Stocks to Watch Monday: Merck, Netflix, Novo Nordisk, Eli Lilly (The Wall Street Journal)
01:26PM	Here's Why Shares of Arcellx Are Up Almost 80% Today (Investopedia)
11:44AM	Gilead acquires CAR-T specialist Arcellx for $7.8bn (Pharmaceutical Technology)
09:37AM	Stocks to Watch Monday: Novo Nordisk, Merck, Domino's, Gilead (The Wall Street Journal)
09:32AM	Alphabet, Nvidia upgraded: Wall Street's top analyst calls (The Fly)
08:46AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
08:16AM	Gilead pays $7.8bn to take full control of promising multiple myeloma therapy (Proactive)
07:54AM	Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion (Reuters)
07:51AM	Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug (Benzinga)
07:42AM	This Biotech Stock Is Surging 78%. Gilead Sciences Agrees to Buy It. (Barrons.com)
07:13AM	Loading…
07:13AM	Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout (MarketWatch)
06:36AM	Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion (The Wall Street Journal)
06:34AM	This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. (Barrons.com)
06:15AM	Gilead to acquire Arcellx for $7.8 billion (Reuters)
06:01AM	Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel (Business Wire)
Feb-16-26 12:23PM	Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study (Insider Monkey)
Feb-04-26 09:00AM	Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder (Business Wire)
Jan-30-26 12:24AM	UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect (Insider Monkey)
Jan-21-26 04:00PM	Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings (Business Wire)
09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
Dec-11-25 07:44AM	Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
Dec-06-25 02:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Nov-30-25 05:42AM	CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting (Insider Monkey)
04:00PM	Loading…
Nov-18-25 04:00PM	Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition (Business Wire)
Nov-05-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition (Business Wire)
Oct-30-25 10:00AM	Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-02-25 08:00AM	Gilead's Lost Decade Is Over. It's Time to Buy the Stock. (Barrons.com)
Sep-03-25 04:00PM	Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-28-25 04:56AM	Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial (Insider Monkey)
Aug-21-25 07:57AM	Gilead dives into in vivo cell therapy with $350M buyout of Interius (BioPharma Dive)
Aug-07-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
06:49AM	EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma (Clinical Trials Arena)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-21-25 04:00PM	Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 (Business Wire) +8.26%
May-20-25 07:46AM	Baron Discovery Fund Initiated a Position in Arcellx (ACLX) (Insider Monkey)
May-14-25 09:30AM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
May-12-25 08:25AM	Here's Why Arcellx (ACLX) Declined in Q1 (Insider Monkey)
May-08-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.27%
04:00PM	Arcellx Provides First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
Apr-29-25 11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 08:49PM	Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-11-25 04:26PM	Arcellx (ACLX): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 04:00PM	Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors (Business Wire)
Feb-27-25 07:05PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.59%
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights (Business Wire)
Feb-26-25 04:00PM	Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-24-25 03:08PM	Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-19-25 10:20AM	Is Arcellx (ACLX) Poised to Capture Significant Market Share? (Insider Monkey)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-10-24 09:00PM	ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma (Clinical Trials Arena) +5.73%
Dec-09-24 04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
07:50AM	Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients (Benzinga)
Dec-08-24 11:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition (Business Wire)
Nov-13-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice (Zacks)
Nov-08-24 09:40AM	Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-07-24 05:15PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.65%
04:00PM	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:41AM	Arcellx price target raised to $106 from $81 at Morgan Stanley (TipRanks)
06:27AM	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Nov-05-24 09:00AM	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study (Business Wire)
07:19AM	Cancer cell therapy from Arcellx, Gilead shows promise in early data (BioPharma Dive)
Oct-31-24 10:43PM	Arcellx (ACLX) Surged in Q3. Heres Why (Insider Monkey)
Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gilson Michelle	Officer	Feb 19 '26	Proposed Sale	68.29	8,384	572,568		Feb 19 08:39 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '26	Option Exercise	0.00	15,340	0	44,302	Feb 19 06:26 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Feb 19 '26	Sale	68.29	8,384	572,568	45,157	Feb 19 06:26 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 02 '26	Option Exercise	0.00	20,496	0	28,962	Feb 18 05:19 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Feb 17 '26	Sale	69.51	11,291	784,783	53,541	Feb 18 05:19 PM
Gilson Michelle	Officer	Feb 17 '26	Proposed Sale	69.51	11,291	784,782		Feb 17 08:36 PM
Lubner David Charles	Director	Jan 20 '26	Option Exercise	6.28	6,000	37,680	27,659	Jan 20 07:59 PM
Lubner David Charles	Director	Jan 20 '26	Sale	75.00	6,000	450,000	21,659	Jan 20 07:59 PM
DAVID LUBNER	Director	Jan 20 '26	Proposed Sale	68.94	15,000	1,034,100		Jan 20 04:27 PM
Heery Christopher	Officer	Jan 14 '26	Proposed Sale	68.51	5,882	402,997		Jan 14 07:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 14 07:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 14 '26	Sale	68.51	5,882	402,997	23,749	Jan 14 07:38 PM
Heery Christopher	Officer	Jan 13 '26	Proposed Sale	65.51	7,437	487,213		Jan 13 09:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 13 '26	Sale	65.51	7,437	487,213	29,631	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 12 09:32 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 12 '26	Sale	64.15	6,131	393,286	37,068	Jan 12 09:32 PM
Heery Christopher	Officer	Jan 12 '26	Proposed Sale	64.15	6,131	393,286		Jan 12 07:34 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 06 08:25 PM
Elghandour Rami	SEE REMARKS	Jan 06 '26	Option Exercise	0.00	55,991	0	782,467	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 03 '26	Option Exercise	0.00	53,098	0	726,476	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 02 '26	Option Exercise	0.00	55,459	0	673,378	Jan 06 08:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 06 '26	Option Exercise	0.00	20,530	0	64,832	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '26	Option Exercise	0.00	15,340	0	44,302	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 02 '26	Option Exercise	0.00	20,496	0	28,962	Jan 06 08:14 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	90.00	340	30,600	284	Nov 17 07:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 15 '25	Sale	91.04	5,364	488,315	8,466	Oct 15 07:28 PM
MICHELLE GILSON	Officer	Oct 15 '25	Proposed Sale	87.33	5,364	468,438		Oct 15 04:38 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 03 '25	Sale	86.00	4,882	419,870	14,894	Oct 06 07:21 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 06 '25	Sale	86.22	1,064	91,733	13,830	Oct 06 07:21 PM
MICHELLE GILSON	Officer	Oct 03 '25	Proposed Sale	82.24	5,946	488,999		Oct 03 04:26 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 30 '25	Sale	81.28	21,034	1,709,723	624	Sep 30 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 29 '25	Sale	80.16	73	5,852	21,658	Sep 29 07:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 26 '25	Sale	80.12	12,396	993,155	21,731	Sep 26 07:45 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 18 '25	Sale	80.01	3,343	267,468	34,427	Sep 19 07:22 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 19 '25	Sale	80.00	300	24,000	34,127	Sep 19 07:22 PM
CHRISTOPHER HEERY	Officer	Sep 18 '25	Proposed Sale	76.42	37,486	2,864,680		Sep 18 04:32 PM
Patel Kavita	Director	Jun 10 '25	Option Exercise	6.66	1,500	9,990	1,500	Jun 11 05:37 PM
Patel Kavita	Director	Jun 10 '25	Sale	67.36	1,500	101,040	0	Jun 11 05:37 PM
KAVITA K PATEL	Director	Jun 10 '25	Proposed Sale	66.86	1,500	100,290		Jun 10 04:25 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '25	Option Exercise	0.00	22,429	0	32,011	May 28 08:18 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	64.14	12,235	784,777	19,776	May 28 08:18 PM
Gilson Michelle	Officer	May 27 '25	Proposed Sale	64.14	12,235	784,776		May 27 06:50 PM
Patel Kavita	Director	May 20 '25	Option Exercise	6.66	1,500	9,990	1,500	May 20 07:58 PM
Patel Kavita	Director	May 20 '25	Sale	58.43	1,500	87,645	0	May 20 07:58 PM
Patel Kavita	Director	Apr 29 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 29 06:34 PM
Patel Kavita	Director	Apr 29 '25	Sale	64.20	1,500	96,300	0	Apr 29 06:34 PM
Yoon Derek	Director	Apr 29 '25	Proposed Sale	62.02	19,470	1,207,529		Apr 29 04:53 PM
Patel Kavita	Director	Apr 08 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 08 07:31 PM
Patel Kavita	Director	Apr 08 '25	Sale	57.50	1,500	86,250	0	Apr 08 07:31 PM
Patel Kavita	Director	Mar 18 '25	Option Exercise	6.66	1,500	9,990	1,500	Mar 18 07:01 PM
Patel Kavita	Director	Mar 18 '25	Sale	71.64	1,500	107,460	0	Mar 18 07:01 PM
Elghandour Rami	SEE REMARKS	Feb 26 '25	Sale	62.02	38,300	2,375,517	149,186	Feb 26 08:13 PM
Elghandour Rami	Officer	Feb 26 '25	Proposed Sale	62.02	38,300	2,375,517		Feb 26 08:11 PM
Patel Kavita	Director	Feb 25 '25	Option Exercise	6.66	1,500	9,990	1,500	Feb 25 07:09 PM
Patel Kavita	Director	Feb 25 '25	Sale	63.16	1,500	94,740	0	Feb 25 07:09 PM
KAVITA K PATEL	Director	Feb 25 '25	Proposed Sale	63.01	7,500	472,575		Feb 25 04:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACLX

Arcellx Inc

Upgrade your FINVIZ experience